Open-Label Extension for Alzheimer's Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC)
Phase of Trial: Phase III
Latest Information Update: 11 Nov 2014
At a glance
- Drugs Semagacestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms IDENTITY-XT
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 02 Aug 2011 Status changed from active, no longer recruiting to completed.
- 17 Dec 2010 Primary endpoint changed from difference in vital signs to changes from baseline in Alzheimer's Disease Assessment Scale - Cognitive subscale and Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory in ClinicalTrials.gov record.